Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase

Department of Cellular and Molecular Medicine, University of California San Diego, 9500 Gilman Dr, La Jolla 92093, California, USA. .
Virology Journal (Impact Factor: 2.18). 11/2013; 10(1):321. DOI: 10.1186/1743-422X-10-321
Source: PubMed


Influenza A virus (IAV) neuraminidase (NA) cleaves sialic acids (Sias) from glycans. Inhibiting NA with oseltamivir suppresses both viral infection, and viral release from cultured human airway epithelial cells. The role of NA in viral exit is well established: it releases budding virions by cleaving Sias from glycoconjugates on infected cells and progeny virions. The role of NA in viral entry remains unclear. Host respiratory epithelia secrete a mucus layer rich in heavily sialylated glycoproteins; these could inhibit viral entry by mimicking sialylated receptors on the cell surface. It has been suggested that NA allows influenza to penetrate the mucus by cleaving these sialylated decoys, but the exact mechanism is not yet established.
We tested IAV interaction with secreted mucus using frozen human trachea/bronchus tissue sections, and bead-bound purified human salivary mucins (HSM) and purified porcine submaxillary mucins (PSM). The protective effect of mucus was analyzed using MDCK cells coated with purified HSM and PSM with known Sia content. Oseltamivir was used to inhibit NA activity, and the fluorescent reporter substrate, 4MU-Neu5Ac, was used to quantify NA activity.
IAV binds to the secreted mucus layer of frozen human trachea/bronchus tissues in a Sia dependent manner. HSM inhibition of IAV infection is Sia dose-dependent, but PSM cannot inhibit infection of underlying cells. HSM competitively inhibits NA cleavage of 4MU-Neu5Ac, reporter substrate. Human IAV effectively cleaves Sias from HSM but not from PSM, and binds to HSM but not to PSM.
IAV interacts with human mucus on frozen tissue sections and mucus-coated beads. Inhibition of IAV infection by sialylated human mucus is dose-dependent, and enhanced when NA is inhibited with oseltamivir. Thus NA cleaves sialylated decoys during initial stages of infection. Understanding IAV interactions with host mucins is a promising new avenue for drug development.

Download full-text


Available from: Robert Schooley, Mar 01, 2014
26 Reads
  • Source
    • "Author Email: virion mobility by preventing the virions from sticking to each other and surrounding mucus [14] [45]. Adamantanes reduce the infection rate by blocking uncoating of the influenza virus once it enters the cell, preventing it from ejecting its genetic code into the cell to be transcribed into new virions [1]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Antivirals are the first line of defence against influenza, so drug efficacy should be re-evaluated for each new strain. However, due to the time and expense involved in assessing the efficacy of drug treatments both in vitro and in vivo, treatment regimens are largely not re-evaluated even when strains are found to be resistant to antivirals. Mathematical models of the infection process can help in this assessment, but for accurate model predictions, we need to measure model parameters characterizing the efficacy of antivirals. We use computer simulations to explore whether in vitro experiments can be used to extract drug efficacy parameters for use in viral kinetics models. We find that the efficacy of neuraminidase inhibitors can be determined by measuring viral load during a single cycle assay, while the efficacy of adamantanes can be determined by measuring infected cells during the preparation stage for the single cycle assay.
    Journal of Biological Dynamics 06/2015; 9(sup1):1-15. DOI:10.1080/17513758.2015.1052764 · 1.03 Impact Factor
  • Source
    • "The human influenza virus attaches to the host cell by binding to Neu5Ac-α2,6-Gal-β1,4-GlcNAc (2,6-linked, in short), a sialic acid modification to glycans that is extremely abundant in humans, especially in the epithelial cells of the upper respiratory tract (Skehel & Wiley, 2000). The mucin that protects the cells in the human upper respiratory tract is equally enriched with Neu5Ac-α2,3-Gal (2,3- linked; Cohen et al., 2013), which is recognized by avian strains of influenza virus (Cone, 2009). Both types of sialylglycans are present in different proportions at different regions of the human respiratory tract, and are essential for a success of the infection by influenza-A (Shynia et al., 2006; Nicholls et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aftermath of influenza infection is determined by a complex set of host-pathogen interactions, where genomic variability on both viral and host sides influences the final outcome. Although there exists large body of literature describing influenza virus variability, only a very small fraction covers the issue of host variance. The goal of this review is to explore the variability of host genes responsible for host-pathogen interactions, paying particular attention to genes responsible for the presence of sialylated glycans in the host endothelial membrane, mucus, genes used by viral immune escape mechanisms, and genes particularly expressed after vaccination, since they are more likely to have a direct influence on the infection outcome.
    Acta biochimica Polonica 09/2014; 61:403-419. · 1.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Influenza B viruses cause annual outbreaks of respiratory illness in humans and are increasingly recognized as a major cause of influenza-associated pediatric mortality. Neuraminidase (NA) inhibitors (NAIs) are the only available therapy for patients infected with influenza B viruses and the potential emergence of NAI-resistant viruses is a public health concern. The NA substitutions located within enzyme active site could not only reduce NAI susceptibility of influenza B virus but also affect virus fitness. In this study we investigated the effect of single NA substitutions on fitness of influenza B/Yamanashi/166/1998 viruses (Yamagata lineage). We generated recombinant viruses containing either WT NA or NA with a substitution in the catalytic (R371K) or framework residues (E119A, D198E, D198Y, I222T, H274Y, N294S). We assessed NAI susceptibility, NA biochemical properties, NA protein expression, and virus replication in vitro and in differentiated normal human bronchial epithelial (NHBE) cells. Our results showed that four NA substitutions (D198E, I222T, H274Y, and N294S) conferred reduced inhibition by oseltamivir and 3 (E119A, D198Y, and R371K) conferred highly reduced inhibition by oseltamivir, zanamivir, and peramivir. All NA substitutions, except for D198Y and R371K, were genetically stable after 7 passages in MDCK cells. Cell surface NA protein expression was significantly increased by H274Y and N294S substitutions. Viruses with E119A, I222T, H274Y, or N294S substitutions were not attenuated in replication efficiency in vitro or in NHBE cells. Overall, viruses with E119A or H274Y NA substitutions possess fitness comparable to NAI-susceptible virus and their acquisition by influenza B viruses should be closely monitored.
    Antimicrobial Agents and Chemotherapy 02/2014; 58(5). DOI:10.1128/AAC.02628-13 · 4.48 Impact Factor
Show more